Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL

Results of a phase I study investigating ibrutinib combined with lenalidomide and rituximab for treatment of diffuse large b-cell lymphoma.